Thank you for registering.
You have joined an exclusive group of Canadian healthcare professionals, who wish to participate in market research.
This is what you can expect as a member of our panel:
- You will receive invitations by email to participate in market research studies that are relevant to your profession. (Please add support@mdanalytics.com to your safe sender list.)
- The survey invitation will always clearly communicate to you the format of the study you are being invited to participate in, estimated length of the study, and the incentive amount.
- As our studies often fill quickly, we urge you to participate as soon as you can.
We do our very best to ensure that the studies we send your way are pertinent to your practice. Keeping your profile up to date will help us better identify studies that are most relevant to you.
All studies that we conduct contain a set of screening questions at the beginning of the study. To learn more about why these are necessary, please read our post on the importance of screeners.
At any time, should you have questions or require support with a study, please contact us and one of our team members will help you.
We look forward to your participation.
Latest Survey Data
Use of Real-World Evidence in Oncology
Real-world evidence (RWE) is no longer a secondary data source, it’s becoming a core input in oncology treatment decisions. In a new survey of Canadian and U.S. oncologists, MD Analytics explores how RWE is being used in clinical practice, the scenarios where it’s most valuable, and what challenges still exist in applying it effectively.
Our latest infographic reveals where oncologists see the greatest benefit from RWE, how it supports complex decision-making, and what pharmaceutical companies can do to improve access, data quality, and clinical relevance.
The Shifting Demographics of Oncology Patients
A recent survey of oncologists in North America reveals a rising trend: more patients are being diagnosed with solid tumor cancers at a younger age. Backed by recent epidemiological studies, this shift is particularly evident in breast and colorectal cancers.
This demographic change is expected to impact treatment strategies, patient management, and how pharmaceutical companies support and communicate with younger patients. Explore the infographic to learn more about the implications for oncology care.
The Building of Stronger MSLs
Medical Science Liaisons (MSLs) play a crucial role in connecting scientific advancements with healthcare professionals. Our latest research highlights what physicians value most in MSL interactions, where key gaps exist, and which companies are leading in specific therapeutic areas.
Explore our new infographic for insights on strengthening MSL impact and delivering greater value to healthcare professionals.